Starting statin therapy shortly after a type 2 diabetes diagnosis may not only protect the heart — it may also be linked to a lower dementia risk.

A large study presented at the European Society of Cardiology Congress in Munich on Aug. 30 found that adults who began taking a statin within one year of their type 2 diabetes diagnosis had a 15% lower relative risk of developing dementia over 10 years compared to those who did not take the medication within five years.

Even for those who delayed starting a statin for one to five years, there was still a 10% lower relative risk, according to the findings, which were published in The Lancet Regional Health – Europe.

3 THINGS TO AVOID IN MIDDLE AGE COULD MEAN 13 MORE YEARS WITHOUT DEMENTIA, STUDY FINDS

A statin is a prescription medication that lowers “bad” LDL cholesterol and helps reduce the risk of heart attack and stroke.

Researchers conducted the study by tracking health data from 132,585 patients in Denmark who were diagnosed with type 2 diabetes between 2006 and 2019 and had no prior history of statin use or dementia.

During a median follow-up of 7.1 years, the team analyzed how the timing of statin treatment impacted overall dementia rates.

Dr. Liron Sinvani, a geriatrician and director for research and innovation at the Northwell Institute for Healthy Aging in New York, said this was a “well-designed, large-scale observational study that adds to a growing body of evidence suggesting that statins may help protect brain health.”

GAME-CHANGING CHOLESTEROL PILL WINS FDA APPROVAL AFTER CUTTING LDL NEARLY 60%

She noted that while a 15% reduction is a modest improvement, it remains “very significant.”

People with type 2 diabetes have an increased risk of cognitive decline and heart disease, consistent with previous research.

Although guidelines generally recommend statins for many adults ages 40 to 75 with diabetes, statin treatment is not always started soon after a type 2 diabetes diagnosis.

The study also examined whether the timing of treatment was linked to dementia risk. People who started statins within a year of their diagnosis had a lower risk than those who did not begin treatment.

CLICK HERE FOR MORE HEALTH STORIES

“The message here is that maybe waiting is actually not the right approach,” Sinvani said, supporting earlier consideration of statin therapy in routine diabetes care.

The expert said she found the results “especially compelling” because the benefit was driven by a lower risk of vascular dementia rather than Alzheimer’s disease.

“The message here is that maybe waiting is actually not the right approach.”

“And that makes biological sense, because we know statins lower cholesterol, reduces inflammation and protects blood vessels,” she added, pointing out that these same mechanisms prevent vascular damage to the brain.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Statin therapy should be viewed as one piece of a broader health strategy alongside exercising regularly, adhering to a healthy diet and staying socially connected, according to the expert.

Almost half of dementia cases may be preventable or delayable by addressing modifiable risk factors, according to the Lancet Commission.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The study did have limitations. Because it was observational rather than a randomized clinical trial, the researchers could not definitively state that statins directly prevent dementia.

As Sinvani cautioned, “This is not proof that statins prevent dementia, but I think it’s an important step in this literature.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The doctor encouraged people with type 2 diabetes who are not taking a statin to ask their doctor whether the medication is appropriate for them.”

A new study warns that driving after eating cannabis edibles can significantly impair road performance and reaction times, even if blood tests show THC levels far below the legal limit.

The findings, published in JAMA Network Open, highlight a potential challenge for impaired-driving enforcement in Canada and some U.S. jurisdictions.

Most previous cannabis-driving studies have involved smoked or inhaled marijuana, which more rapidly spikes levels of THC (tetrahydrocannabinol, the main psychoactive compound in cannabis) in the bloodstream.

AMERICA HITS MAJOR MARIJUANA MILESTONE AS DAILY WEED USE SURPASSES DAILY DRINKING

Edibles are absorbed more slowly and can produce driving impairment even when blood THC concentrations remain relatively low.

Researchers found that drivers who consumed higher doses of edible THC struggled with lane control, had slower reaction times and experienced greater speed fluctuations. Yet, their blood tests stayed below the standard legal cutoff used to prove impairment at roadside traffic stops.

To assess how oral cannabis impacts driving, researchers at the Centre for Addiction and Mental Health in Toronto conducted a trial with 40 healthy adult volunteers who regularly use cannabis.

Each participant attended four separate sessions in which they consumed soft-chew gummies containing either 0, 2, 10 or 20 milligrams of THC.

CANNABIS COMPOUNDS COULD REVERSE DISEASE AFFECTING ONE-THIRD OF ADULTS

The researchers then tested the drivers using a driving simulator at two, five and 24 hours after consumption, tracking how well drivers stayed in their lane, how quickly they reacted to road events and how consistently they maintained their speed.

Blood samples and self-reported ratings of intoxication were also collected.

The results showed driving impairment at two and five hours after consuming 10- and 20-milligram gummies. Compared with placebo, participants who consumed those doses had greater variability in lane position, while the 20-milligram dose was also linked to slower reaction times and less consistent speed control.

Participants also recognized their own limitations, reporting a lower willingness to drive and reduced confidence in their driving skills after taking the gummies.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The highest blood THC concentrations averaged 1.6 nanograms per milliliter after the 10-milligram dose and 3.4 nanograms per milliliter after the 20-milligram dose. Those levels were below the commonly used 5-ng/mL threshold, although THC limits vary by jurisdiction and some individual samples exceeded 5 ng/mL.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

By comparison, participants in the team’s previous smoked-cannabis study showed similar levels of impairment while reaching an average peak blood THC concentration of 30.3 nanograms per milliliter, nearly 10 times higher than the 20-milligram edible group.

The study did have some limitations. Tests were conducted on virtual simulators rather than actual roads, meaning drivers faced no real physical risk during the experiments. It also focused on regular cannabis users, so it is unclear how occasional users might react to similar doses.

Additionally, minimal residual effects were detected after 24 hours. While maximum speed remained slightly higher among participants on the 10-milligram and 20-milligram doses, subjective feelings of intoxication had completely faded.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

In an accompanying commentary, Dr. José Ignacio Nazif-Munoz of the Université de Sherbrooke noted that these biological differences pose a challenge for law enforcement.

CLICK HERE FOR MORE HEALTH STORIES

Because edibles are absorbed slowly through the digestive system, standard blood tests may fail to identify unsafe drivers, leaving policymakers searching for more reliable roadside tools.

“The delayed absorption and prolonged duration of effects of edible cannabis distinguish it from smoked or inhaled cannabis, complicating the interpretation of biological measures,” he wrote.

Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.